URO-VAXOM^Ò TREATMENT REDUCED THE NUMBER OF RECIDIVES OF RECURRENT URINARY TRACT INFECTIONS

Kiraly B., Andits M., Oroszlan Gy.

Markusovszky Teaching Hospital Szombathely, Hungary

Objective: The aim of the study was to evaluate the efficacy of Uro-Vaxom^Ò treatment among children with recurrent urinary tract infections (UTI).

Patients and methods: 20 children (age 2 �C18 year) who had at least 3 UTI during a one year period were enrolled into the study. Uro-Vaxom^Ò treatment was started after initial laboratory and microbiological investigations. Renal ultrasound and voiding cystogram were also made in all cases. The prophylactic dose of Uro-Vaxom^Ò was 1 capsule/die for 90 consecutive days. The patients were followed up for a one year period. The number of recurrences and the use of antibiotics were registered.

Results: The number of recurrences of the UTIs was 3,64/patient/year before Uro-Vaxom^Ò treatment. The number of recidives was reduced to 1,04/patient/year during and after the Uro-Vaxom^Ò treatment. The difference was strongly significant (p< 0,001). The recidive free period was 18,2 week/patient/year before treatment vs. 37,66 week/patient/year after treatment (p< 0,001). Antibiotic therapy was indicated 3,12 times/patient/year before Uro-Vaxom^Ò treatment whereas only 1,04times/patient/year during the study period. Escherichia coli was isolated as the most common pathogen. No side effects were observed during the study period.

Conclusion: Uro-Vaxom^Ò serves as an effective adjuvant therapy for the treatment of recurrent UTI in children. The number of recurrence of UTI is significantly reduced in the Uro-Vaxom^Ò treated group. The administration of Uro-Vaxom^Ò is safe, no side effects were observed during its use.

1904